| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-3795 |
| P698 | PubMed publication ID | 21343397 |
| P2093 | author name string | José Baselga | |
| Joaquín Arribas | |||
| Kim Pedersen | |||
| Josep Lluís Parra-Palau | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 1515-1519 | |
| P577 | publication date | 2011-02-22 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | p95HER2 and breast cancer | |
| P478 | volume | 71 |
| Q41820672 | "Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas. |
| Q104073477 | 3D projection electrophoresis for single-cell immunoblotting |
| Q57284386 | A Platform To Enhance Quantitative Single Molecule Localization Microscopy |
| Q54508329 | A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. |
| Q28485310 | A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers |
| Q37341891 | A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression |
| Q41344028 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience |
| Q48134448 | A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells |
| Q64928480 | A toolkit for studying cell surface shedding of diverse transmembrane receptors. |
| Q26773907 | Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q26797471 | Analysis of different HER-2 mutations in breast cancer progression and drug resistance |
| Q34318275 | Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells |
| Q35012494 | BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway |
| Q38150774 | Biomarkers of drugs targeting HER-family signalling in cancer. |
| Q58617435 | Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety |
| Q35945009 | CX3CL1 promotes breast cancer via transactivation of the EGF pathway |
| Q54495128 | Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61γ) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer. |
| Q28728701 | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer |
| Q38111772 | Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues |
| Q47170552 | DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer |
| Q41846641 | Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells |
| Q37722926 | Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response |
| Q26785612 | Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer |
| Q34714574 | Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts |
| Q26863231 | EGFR/HER-targeted therapeutics in ovarian cancer |
| Q34736064 | Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q54957080 | Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. |
| Q37447938 | Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines |
| Q57117017 | Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q64069811 | HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 |
| Q33737278 | HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance |
| Q57283292 | HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q33966430 | Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer |
| Q89477386 | Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer |
| Q36009610 | Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer |
| Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| Q35977527 | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| Q35624814 | Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance |
| Q38034816 | Mechanisms of acquired resistance to targeted cancer therapies. |
| Q26772969 | Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer |
| Q36810717 | Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 |
| Q52876533 | Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells. |
| Q91933716 | Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis |
| Q26764879 | Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab |
| Q37381579 | Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer |
| Q38718320 | Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. |
| Q47130450 | Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. |
| Q90482989 | Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade |
| Q37444430 | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. |
| Q64934294 | Personalized medicine in breast cancer: pharmacogenomics approaches. |
| Q38848389 | Perspectives of HER2-targeting in gastric and esophageal cancer |
| Q39701009 | Pertuzumab and trastuzumab: the rationale way to synergy |
| Q92376425 | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer |
| Q39297048 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck |
| Q36064908 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer |
| Q36113481 | Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases |
| Q41346146 | Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases |
| Q34308692 | Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers |
| Q26830216 | Receptor tyrosine kinases in the nucleus |
| Q47186997 | Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. |
| Q41135384 | Screening and identification of small molecule inhibitors of ErbB2-induced invasion. |
| Q38253835 | Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. |
| Q39207632 | TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line |
| Q36064912 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer |
| Q38890318 | The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness |
| Q34120685 | Therapeutic targeting of integrin αvβ6 in breast cancer |
| Q38974785 | Trastuzumab cardiotoxicity: from clinical trials to experimental studies |
| Q33759627 | Trastuzumab emtansine: mechanisms of action and drug resistance |
| Q38673589 | When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase |
| Q39794283 | [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer |
| Q57042030 | p95HER2-T cell bispecific antibody for breast cancer treatment |
Search more.